

Supplementary Information

Palladium-catalyzed Asymmetric Carbofluorination of *gem*-Difluorostyrenes with Cesium Fluoride and Allylic Acetates

Eryn Nelson, Rajesh K. Bisoyi, and Christian Wolf *


Department of Chemistry, Georgetown University, 37th and O St., Washington DC 20057, USA.
Email: cw27@georgetown.edu

<u>Contents</u>	<u>Page</u>
1. General information	S2
2. Synthesis of <i>gem</i> -difluoroalkenes	S3
3. Reaction optimization	S6
3.1. Solvent screening	S6
3.2. Fluoride source and additives screening	S7
3.3. Ligand screening	S8
4. Product synthesis and characterization	S9
5. Product derivatizations	S23
6. ¹ H, ¹³ C, and ¹⁹ F NMR spectra	S27
7. HPLC chromatograms	S51
8. Crystallographic data	S68
9. References	S71



1. General information

Commercially available ligands, catalysts, (*E*)-1,3-diphenylallyl acetate, cesium fluoride, 18-crown-6, reagents and solvents were used as purchased without further purification. *Gem*-difluoroalkenes^{1,2} and (*E*)-1,3-diaryllallyl acetates^{3,4} were synthesized by following literature procedures. NMR spectra were obtained at 400 MHz (¹H NMR), 376 MHz (¹⁹F NMR), and 100 MHz (¹³C NMR) in deuterated chloroform. Reaction products were purified by column chromatography on silica gel as described below. All reactions were carried out under nitrogen atmosphere unless otherwise noted. HPLC enantioseparations using Chiralpak AD-H were performed at room temperature with a flow rate of 1.0 mL/min using hexanes:IPA mixtures.

Ligands used in this study (**L1-L17**):




2. Synthesis of *gem*-difluoroalkenes




Method I (1a-d, 1i-l): The aldehyde (2.5 mmol) and PPh₃ (5.0 mmol) were dissolved in 4 mL NMP and heated to 100 °C. Sodium chlorodifluoroacetate (5.0 mmol) was added and the reaction was stirred for 15 minutes at 100 °C. The solution was cooled to room temperature, quenched with water, and extracted with ethyl acetate (3 x 10 mL). The organic layer was washed with 1.5 mL 30% H₂O₂ followed by brine, then dried over Na₂SO₄ and purified by silica gel chromatography using EtOAc:hexanes as the eluent.

Method II (1e-g, 1m): The aldehyde (2.5 mmol) and PPh₃ (2.5 mmol) were dissolved in 4 mL NMP and heated to 100 °C. Sodium chlorodifluoroacetate (2.5 mmol) was added and the reaction was stirred for 15 minutes at 100 °C. The solution was cooled to room temperature, quenched with water, and extracted with ethyl acetate (3 x 10 mL). The organic layer was washed with 1.5 mL 30% H₂O₂ followed by brine, then dried over Na₂SO₄ and purified by silica gel chromatography using EtOAc:hexanes as the eluent.


NMR spectra of **1a-f** and **1h-j** were in agreement with literature reports.^{1,2}




4-(2,2-Difluorovinyl)-2-methyl-1-nitrobenzene (1g). Compound **1g** was obtained as a colorless oil in 25% yield (125 mg, 0.63 mmol) using Method II. ^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, $J = 8.5$ Hz, 1H), 7.31 – 7.21 (m, 2H), 5.30 (dd, $J = 25.6, 3.4$ Hz, 1H), 2.58 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.0 (dd, $J_{\text{C-F}} = 301.3, 292.2$ Hz), 147.3, 135.7 (dd, $J_{\text{C-F}} = 7.6, 6.4$ Hz), 134.3, 131.6 (dd, $J_{\text{C-F}} = 6.5, 3.8$ Hz), 125.7 (dd, $J_{\text{C-F}} = 7.3, 3.4$ Hz), 125.3, 81.4 (dd, $J_{\text{C-F}} = 30.5, 12.9$ Hz), 20.7. ^{19}F NMR (376 MHz, CDCl_3) δ -78.05 (dd, $J = 25.5, 20.3$ Hz), -79.48 (dd, $J = 20.5, 3.7$ Hz). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_9\text{H}_7\text{F}_2\text{NO}_2$ 200.0518, found 200.0517.



4-Bromo-2-chloro-1-(2,2-difluorovinyl)benzene (1k). Compound **1k** was obtained as a colorless oil in 61% yield (390 mg, 1.5 mmol) using Method I. ^1H NMR (400 MHz, CDCl_3) δ 7.52 (d, $J = 0.7$ Hz, 1H), 7.40 – 7.30 (m, 2H), 5.61 (dd, $J = 21.8, 3.6$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.7 (dd, $J_{\text{C-F}} = 299.4, 289.9$ Hz), 133.5 (dd, $J_{\text{C-F}} = 5.5, 2.1$ Hz), 132.2, 130.2, 129.7 (dd, $J_{\text{C-F}} = 10.2, 1.6$ Hz), 127.6 (dd, $J_{\text{C-F}} = 7.8, 6.2$ Hz), 121.0 (dd, $J_{\text{C-F}} = 2.1, 2.1$ Hz), 78.4 (dd, $J_{\text{C-F}} = 33.5, 12.2$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -80.33 (dd, $J = 23.8, 3.5$ Hz), -81.19 (dd, $J = 24.6, 24.6$ Hz). Attempts to obtain elemental analysis and HRMS data were unsuccessful due to the high volatility of this compound.




5-Bromo-2-(2,2-difluorovinyl)-1,3-difluorobenzene (1l). Compound **1l** was obtained as a colorless oil in 56% yield (363 mg, 1.4 mmol) using Method I. ^1H NMR (400 MHz, CDCl_3) δ 7.12 – 7.03 (m, 2H), 5.14 (dd, $J = 25.9, 2.1$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.1 (ddt, $J_{\text{C-F}} = 254.9, 8.6, 1.6$ Hz), 157.8 (ddt, $J_{\text{C-F}} = 290.0, 289.4, 1.6$ Hz), 121.2 (dd, $J_{\text{C-F}} = 12.3$ Hz), 115.3 (td, $J_{\text{C-F}} = 29.4, 25.1, 12.9$ Hz), 106.9 (tdd, $J_{\text{C-F}} = 19.3, 8.1, 4.1$ Hz), 68.9 (ddt, $J_{\text{C-F}} = 37.5, 18.3, 2.4$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -75.78 (dddd, $J = 24.7, 24.7, 16.2, 16.2$ Hz), -80.48 (dddd, $J = 16.2, 16.2, 3.3, 3.3$ Hz), -109.15 (ddd, $J = 24.2, 10.8, 2.9$ Hz). Attempts to obtain elemental analysis and HRMS data were unsuccessful due to the high volatility of this compound.



1-Bromo-4-(2,2-difluorovinyl)-2-nitrobenzene (1m). Compound **1m** was obtained as a yellow solid in 24% yield (311 mg, 1.18 mmol) using Method II. ^1H NMR (400 MHz, CDCl_3) δ 7.77 (d, $J = 2.2$ Hz, 1H), 7.68 (d, $J = 8.4$ Hz, 1H), 7.36 (dd, $J = 8.4, 2.2$ Hz, 1H), 5.30 (dd, $J = 25.0, 3.0$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.0 (dd, $J = 300.4, 292.5$ Hz), 150.1, 135.3, 131.7 (dd, $J = 6.8, 3.5$ Hz), 131.3 (dd, $J = 7.7, 6.1$ Hz), 124.2 (dd, $J = 6.9, 3.8$ Hz), 112.4 (dd, $J = 2.6, 2.6$ Hz), 80.6 (dd, $J = 31.5, 13.2$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -77.91 (dd, $J = 25.1, 21.7$ Hz), -79.58 (dd, $J = 21.5, 3.0$ Hz). EA Found: C, 36.8; H, 1.7; N, 5.2. $\text{C}_8\text{H}_4\text{BrF}_2\text{NO}_2$ requires C, 36.4; H, 1.5; N, 5.3%.

3. Reaction optimization


3.1. Solvent screening^a



Entry	Solvent	Conversion ^b	3aa : 3aa' ^c	<i>dr</i> ^d	<i>ee</i> (major) ^e
1	DCM	83%	11 : 1	1 : 3.6	87%
2	ACN	100%	5 : 1	1 : 2.6	92%
3	acetone	100%	2 : 1	1 : 2.8	87%
4	TBME	55%	4 : 1	1 : 3.0	87%
5	EtOAc	100%	6 : 1	1 : 2.8	85%
6	PhCN	100%	1 : 1	1 : 2.9	n.d.
7	dioxane	83%	3 : 1	1 : 1.7	n.d.
8	toluene	85%	3 : 1	1 : 2.9	n.d.
9	DMF	100%	4 : 1	1 : 2.3	n.d.

[a] Reaction conditions: **L1** (5 mol%), $[\text{allylPdCl}]_2$ (2.5 mol%), **1a** (0.15 mmol), **2a** (0.3 mmol), CsF (0.18 mmol), and 18-crown-6 (0.18 mmol) in 1.0 mL of solvent at 25 °C. [b] Conversion of **1a** determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [c] Determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [d] Determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [e] Determined by Chiral HPLC using Chiralpak AD-H. n.d. = not determined.


3.2. Fluoride source and additives screening^a



Entry	Fluoride source	additive	Conversion ^b	3aa : 3aa' ^c	<i>dr</i> ^d	<i>ee</i> (major) ^e
1	CsF	none	20%	21 : 1	1 : 3.5	83%
2	CsF	18-crown-6	83%	11 : 1	1 : 3.6	87%
3 ^f	CsF	18-crown-6	n.r.	-	-	-
4	AgF	18-crown-6	n.r.	-	-	-
5	KF	18-crown-6	64%	1 : 3.5	1 : 3.6	n.d.
6	TBAF ₂ Ph ₃ Sn	none	n.r.	-	-	-

[a] Reaction conditions: **L1** (5 mol%), [allylPdCl]₂ (2.5 mol%), **1a** (0.15 mmol), **2a** (0.3 mmol), fluoride source (0.18 mmol), and additive (0.18 mmol) in 1.0 mL of CH₂Cl₂ at 25 °C. [b] Conversion of **1a** determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [c] Determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [d] Determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [e] Determined by Chiral HPLC using Chiralpak AD-H. [f] Reaction was run without [allylPdCl]₂. n.r. = no reaction. n.d. = not determined.


3.3. Ligand screening^a



Entry	Ligand	Conversion ^b	3aa : 3aa' ^c	<i>dr</i> ^d	<i>ee</i> (major) ^e
1	L1	100%	5 : 1	1 : 2.6	92%
2	L2	100%	2 : 1	1 : 4.9	n.d.
3 ^f	L3	67%	2 : 1	1 : 1.8	>99%
4 ^f	L4	66%	3 : 1	1 : 2.2	95%
5	L5	100%	3 : 1	1 : 2.0	n.d.
6	L6	100%	1 : 1	1 : 2.9	n.d.
7	L7	77%	1 : 1	1 : 1.5	n.d.
8	L8	89%	1 : 3	1 : 2.7	n.d.
9	L9	89%	1 : 1	1 : 2.6	n.d.
10	L10	100%	3 : 1	1:3.4	n.d.
11 ^g	L11	100%	10 : 1	1 : 3	n.d.
12	L12	100%	5 : 1	1 : 2.7	n.d.
13 ^h	L13	100%	12 : 1	1 : 4.4	80%
14 ^h	L14	100%	6 : 1	1 : 1.5	n.d.
15 ^h	L15	79%	1 : 1	1 : 3.0	n.d.
16 ^h	L16	100%	1 : 7	1 : 3.7	n.d.
17 ^h	L17	100%	24:1	1 : 3.5	n.d.
18 ^{g,h}	L17	100%	16:1	1:4.3	91%

[a] Reaction conditions: ligand (5 mol%), [allylPdCl]₂ (2.5 mol%), **1a** (0.15 mmol), **2a** (0.3 mmol), CsF (0.18 mmol), and 18-crown-6 (0.18 mmol) in 1.0 mL of acetonitrile at 25 °C. [b] Conversion of **1a** determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [c] Determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [d] Determined by ¹⁹F NMR spectroscopy of the crude reaction mixture. [e] Determined by Chiral HPLC using Chiralpak AD-H. [f] Reaction was run in 1.0 mL dichloromethane. [g] Reaction was run at -40 °C. [h] Reaction was run for 24 h. n.d. = not determined.


4. Product synthesis and characterization




Method A: In an 8 mL vial under nitrogen atmosphere, [allylPdCl]₂ (5 mol%, 1.4 mg), ligand (10 mol%, 5.1 mg), CsF (0.09 mmol, 14 mg), and 18-crown-6 (0.09 mmol, 24 mg) were dissolved in 300.0 μL ACN and stirred for 5 minutes. Allylic acetate (0.09 mmol) was dissolved in 50.0 μL ACN then added to the reaction mixture. The solution was stirred for 5 minutes and then cooled to -40 °C. A solution of difluoroalkene (0.075 mmol) in 150.0 μL ACN was added at -40 °C and the reaction was stirred overnight. After 24 hours, the crude reaction mixture was purified via flash chromatography on silica gel using EtOAc:hexanes as the eluent.

Method B: In an 8 mL vial under nitrogen atmosphere, [allylPdCl]₂ (5 mol%, 1.4 mg), ligand (10 mol%, 5.1 mg), CsF (0.09 mmol, 14 mg), and 18-crown-6 (0.09 mmol, 24 mg) were dissolved in 300.0 μL ACN and stirred for 5 minutes. Allylic acetate (0.188 mmol) was dissolved in 50.0 μL ACN and then added to the reaction mixture. The solution was stirred for 5 minutes then cooled


to -40 °C. A solution of difluoroalkene (0.075 mmol) in 150.0 μ L ACN was added slowly at -40 °C (10.0 μ L every 30 min.) and the reaction was stirred overnight. After 24 hours the crude reaction mixture was purified via flash chromatography on silica gel using EtOAc:hexanes as the eluent.



Methyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3aa). Compound **3aa** was obtained as a colorless oil in 79% yield (57.8 mg, 0.14 mmol) using Method A. The *dr* was determined to be 1:4 by ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer 91% *ee*, t_R (major) = 10.2 min., t_R (minor) = 12.2 min.; minor diastereomer 94% *ee*, t_R (major) = 18.1 min., t_R (minor) = 20.2 min. ^1H NMR (400 MHz, CDCl_3) δ 8.02 (d, $J = 8.3$ Hz, 2H), 7.39 – 7.28 (m, 5H), 7.24 – 7.19 (m, 5H), 7.14 – 7.11 (m, 2H), 6.28 (d, $J = 15.7$ Hz, 1H), 6.08 (dd, $J = 15.7, 9.0$ Hz, 1H), 4.19 (dd, $J = 8.5, 8.5$ Hz, 1H), 3.90 (s, 3H), 3.82 (dq, $J = 8.8$ Hz, 8.8 Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 169.3, 143.9, 141.3, 139.5, 135.3, 132.5, 132.4, 131.5 (q, $J_{\text{C-F}} = 282.8$ Hz), 131.4, 131.2, 131.1, 130.5, 130.2, 129.8, 128.9, 58.8 (q, $J_{\text{C-F}} = 25.1$ Hz), 54.8, 52.0. ^{19}F NMR (376 MHz, CDCl_3) δ -63.29 (d, $J = 8.9$ Hz, minor diastereomer), -64.42 (d, $J = 9.2$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{21}\text{F}_3\text{O}_2$ 411.1566, found 411.1571.




Ethyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3ba). Compound **3ba** was obtained as a colorless oil in 75% yield (24.6 mg, 0.058 mmol) using Method A. The *dr* was determined to be 1:5 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 92% *ee*, t_R (major) = 8.5 min., t_R (minor) = 11.5 min.; minor diastereomer, >99% *ee*, t_R (major) = 15.1 min., t_R (minor) = 16.1 min. ^1H NMR (400 MHz, CDCl_3) δ 8.04 – 7.97 (m, 2H), 7.38 – 7.25 (m, 5H), 7.23 – 7.18 (m, 4H), 7.16 – 7.10 (m, 3H), 6.27 (d, $J = 15.7$ Hz, 1H), 6.08 (dd, $J = 15.7$, 8.9 Hz, 1H), 4.36 (q, $J = 7.1$ Hz, 2H), 4.18 (dd, $J = 8.5$, 8.5 Hz, 1H), 3.82 (dq, $J = 9.0$, 9.0 Hz, 1H), 1.38 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 168.8, 143.9, 141.1, 139.5, 135.3, 133.1, 132.5, 132.4, 131.4, 131.2, 131.1, 131.1 (q, $J_{\text{C-F}} = 280.5$ Hz), 130.5, 130.2, 129.8, 128.9, 63.8, 58.8 (q, $J_{\text{C-F}} = 24.6$ Hz), 52.0, 17.0. ^{19}F NMR (376 MHz, CDCl_3) δ -63.34 (d, $J = 9.0$ Hz, minor diastereomer), -64.49 (d, $J = 9.0$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{23}\text{F}_3\text{O}_2$ 425.1723, found 425.1726.




(*E*)-1-(4-(1,1,1-Trifluoro-3,5-diphenylpent-4-en-2-yl)phenyl)ethan-1-one (3ca). Compound **3ca** was obtained as a colorless oil in 64% yield (34 mg, 0.087 mmol) using Method A. The *dr* was determined to be 1:6 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC

(CHIRALPAK AD-H, Hexanes/IPA 98:2, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 93 % *ee*, t_R (major) = 12.6 min., t_R (minor) = 16.5 min.; minor diastereomer, >99% *ee*, t_R (major) = 39.4 min., t_R (minor) = 37.3 min. ^1H NMR (400 MHz, CDCl_3) δ 7.92 (d, $J = 8.4$ Hz, 2H), 7.39 – 7.25 (m, 5H), 7.23 – 7.09 (m, 7H), 6.27 (d, $J = 15.7$ Hz, 1H), 6.07 (dd, $J = 15.7, 9.0$ Hz, 1H), 4.18 (dd, $J = 8.5, 8.5$ Hz, 1H), 3.83 (dq, $J = 8.9, 8.9$ Hz, 1H), 2.58 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 200.2, 143.9, 141.4, 139.5, 139.4, 135.4, 132.7, 131.4, 131.1, 130.7 (q, $J_{\text{C-F}} = 261.7$ Hz), 130.5, 130.2, 128.9, 58.7 (q, $J_{\text{C-F}} = 24.9$ Hz), 52.0, 29.3. ^{19}F NMR (376 MHz, CDCl_3) δ -64.44 (d, $J = 9.1$ Hz). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{21}\text{F}_3\text{O}$ 395.1617, found 395.1622.




(E)-4-(1,1,1-Trifluoro-3,5-diphenylpent-4-en-2-yl)benzaldehyde (3da). Compound **3da** was obtained as a colorless oil in 53% yield (17 mg, 0.044 mmol) using Method B. The *dr* was determined to be 1:4 by ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1 to 98:2, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 94% *ee*, t_R (major) = 21.5 min., t_R (minor) = 26.6 min.; minor diastereomer, >99% *ee*, t_R (major) = 115.3 min. ^1H NMR (400 MHz, CDCl_3) δ 10.00 (s, 1H), 7.85 (d, $J = 8.3$ Hz, 2H), 7.45 (d, $J = 7.9$ Hz, 2H), 7.35 – 7.29 (m, 3H), 7.25 – 7.17 (m, 5H), 7.13 – 7.08 (m, 2H), 6.27 (d, $J = 15.7$ Hz, 1H), 6.06 (dd, $J = 15.7, 9.0$ Hz, 1H), 4.18 (dd, $J = 8.6, 8.6$ Hz, 1H), 3.85 (dq, $J = 8.6, 8.6$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 194.3, 143.7, 143.0, 139.3, 138.8, 135.5, 133.1, 132.4, 131.5, 131.2, 131.1 (q, $J_{\text{C-F}} = 280.7$ Hz), 131.0, 130.5, 130.3, 129.9, 128.8, 58.9 (q, $J_{\text{C-F}} = 25.6$ Hz), 52.1. ^{19}F NMR (376 MHz, CDCl_3) δ -63.20 (d, $J = 8.9$ Hz, minor diastereomer), -64.31 (d, J

= 8.9 Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[M+H]^+$ calcd for $C_{24}H_{19}F_3O$ 381.1461, found 381.1462.




(E)-(5,5,5-Trifluoro-4-(4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ea). Compound **3ea** was obtained as a colorless oil in 67% yield (20 mg, 0.050 mmol) using Method B. The *dr* was determined to be 1:4 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 94% *ee*, t_R (major) = 12.0 min., t_R (minor) = 14.1 min.; minor diastereomer, >99% *ee*, t_R (major) = 33.3 min., t_R (minor) = 54.2 min. 1H NMR (400 MHz, $CDCl_3$) δ 8.20 (d, $J = 8.4$ Hz, 2H), 7.44 (d, $J = 8.4$ Hz, 2H), 7.37 – 7.30 (m, 2H), 7.23 – 7.19 (m, 3H), 7.15 – 7.10 (m, 5H), 6.30 (d, $J = 15.7$ Hz, 1H), 6.04 (dd, $J = 15.6, 9.2$ Hz, 1H), 4.19 (dd, $J = 8.7, 8.7$ Hz, 1H), 3.90 (dq, $J = 8.5, 8.5$ Hz, 1H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 150.5, 143.5, 143.4, 139.1, 135.8, 133.4, 131.6, 131.2, 130.6 (q, $J_{C-F} = 280.9$ Hz), 130.5, 130.4, 130.1, 129.1, 128.9, 126.3, 58.6 (q, $J_{C-F} = 25.1$ Hz), 52.1. ^{19}F NMR (376 MHz, $CDCl_3$) δ -63.24 (d, $J = 8.8$ Hz, minor diastereomer), -64.35 (d, $J = 8.8$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[M-H]^-$ calcd for $C_{23}H_{18}F_3NO_2$ 396.1217, found 396.1207.



(E)-(5,5,5-Trifluoro-4-(4-(methylsulfonyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3fa).


Compound **3fa** was obtained as a pale yellow oil in 74% yield (51 mg, 0.12 mmol) using Method B. The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 95:5, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, >99% *ee*, t_R (major) = 23.4 min., t_R (minor) = 24.7 min.; minor diastereomer, >99% *ee*, t_R (major) = 46.4 min., t_R (minor) = 57.9 min. ^1H NMR (400 MHz, CDCl_3) δ 7.91 (d, $J = 8.4$ Hz, 2H), 7.47 (d, $J = 8.2$ Hz, 2H), 7.37 – 7.28 (m, 4H), 7.23 – 7.18 (m, 4H), 7.14 – 7.10 (m, 2H), 6.29 (d, $J = 15.7$ Hz, 1H), 6.04 (dd, $J = 15.7, 9.1$ Hz, 1H), 4.19 (dd, $J = 8.6, 8.6$ Hz, 1H), 3.89 (dq, $J = 8.7, 8.7$ Hz, 1H), 3.01 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 143.5, 143.1, 142.5, 139.2, 135.8, 133.5, 131.5, 131.2, 130.9 (q, $J_{\text{C-F}} = 283.5$ Hz), 130.5, 130.4, 130.2, 130.1, 130.0, 128.9, 58.8 (q, $J_{\text{C-F}} = 25.3$ Hz), 52.0, 47.1. ^{19}F NMR (376 MHz, CDCl_3) δ -63.17 (d, $J = 8.8$ Hz, minor diastereomer), -64.32 (d, $J = 9.0$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{21}\text{F}_3\text{O}_2\text{S}$ 431.1287, found 431.1290.



(E)-(5,5,5-Trifluoro-4-(3-methyl-4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ga).


Compound **3ga** was obtained as a pale yellow oil in 71% yield (44 mg, 0.11 mmol) using Method B. The *dr* was determined to be 1:4 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by

HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 89% *ee*, t_R (major) = 9.5 min., t_R (minor) = 10.5 min.; minor diastereomer, >99% *ee*, t_R (major) = 21.2 min., t_R (minor) = 23.1 min. ^1H NMR (400 MHz, CDCl_3) δ 7.97 (d, $J = 8.5$ Hz, 1H), 7.38 – 7.31 (m, 3H), 7.31 – 7.17 (m, 7H), 7.17 – 7.12 (m, 2H), 6.31 (m, 1H), 6.06 (dd, $J = 15.7, 9.0$ Hz, 1H), 4.18 (dd, $J = 8.7, 8.7$ Hz, 1H), 3.83 (dq, $J = 8.9, 8.9$ Hz, 1H), 2.59 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 151.4, 143.6, 141.7, 139.3, 137.0, 136.6, 136.4, 135.7, 131.5, 131.2, 130.8, 130.7, 130.4, 130.3 (q, $J_{\text{C-F}} = 281.8$ Hz), 130.0, 128.9, 127.6, 58.4 (q, $J_{\text{C-F}} = 25.2$ Hz), 51.9, 23.3. ^{19}F NMR (376 MHz, CDCl_3) δ -63.22 (d, $J = 8.9$ Hz, minor diastereomer), -64.34 (d, $J = 8.9$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{20}\text{F}_3\text{NO}_2$ 412.1519, found 412.1522.




(*E*)-4-(1,1,1-Trifluoro-3,5-diphenylpent-4-en-2-yl)benzonitrile (3ha). Compound **3ha** (1414) was obtained as a colorless oil in 79% yield (32.5 mg, 0.086 mmol) using Method A. The *dr* was determined to be 1:4 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 88% *ee*, t_R (major) = 18.5 min., t_R (minor) = 20.0 min.; minor diastereomer, > 99% *ee*, t_R (major) = 55.7 min., t_R (minor) = 57.5 min. ^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, $J = 8.4$ Hz, 2H), 7.41 – 7.25 (m, 6H), 7.23 – 7.09 (m, 6H), 6.28 (d, $J = 15.7$ Hz, 1H), 6.03 (dd, $J = 15.7, 9.1$ Hz, 1H), 4.16 (dd, $J = 8.7, 8.7$ Hz, 1H), 3.83 (dq, $J = 8.6, 8.6$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 143.5, 141.6, 139.2, 135.7, 134.9, 133.2, 131.5, 131.2, 130.9 (q, $J_{\text{C-F}} = 281.7$ Hz), 130.6, 130.4, 130.0,

128.9, 121.0, 115.1, 58.9 (q, $J_{C-F} = 25.2$ Hz), 52.0. ^{19}F NMR (376 MHz, CDCl_3) δ -63.24 (d, $J = 8.7$ Hz, minor diastereomer), -64.35 (d, $J = 8.9$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{24}\text{H}_{18}\text{F}_3\text{N}$ 376.1308, found 376.1311.




(E)-5,5,5-Trifluoro-4-(4-(trifluoromethyl)phenyl)pent-1-ene-1,3-diyl dibenzene (3ia).

Compound **3ia** was obtained as a colorless oil in 60% yield (37.5 mg, 0.089 mmol) using Method A. The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 96% *ee*, t_R (major) = 7.7 min., t_R (minor) = 7.3 min.; minor diastereomer, >99% *ee*, t_R (major) = 14.3 min., t_R (minor) = 12.9 min. ^1H NMR (400 MHz, CDCl_3) δ 7.60 (d, $J = 8.1$ Hz, 2H), 7.40 – 7.32 (m, 6H), 7.25 – 7.18 (m, 3H), 7.16 – 7.11 (m, 3H), 6.30 (d, $J = 15.7$ Hz, 1H), 6.07 (dd, $J = 15.7, 9.0$ Hz, 1H), 4.19 (dd, $J = 8.5, 8.5$ Hz, 1H), 3.83 (dq, $J = 9.03, 8.78$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 141.1, 136.7, 132.9, 130.2, 128.8, 128.7, 128.5, 127.8, 127.8, 127.6, 127.4 (q, $J_{C-F} = 281.4$ Hz), 127.4 (q, $J_{C-F} = 272.9$ Hz), 127.2, 126.4, 126.2, 125.5 (q, $J_{C-F} = 3.8$ Hz), 55.9 (q, $J_{C-F} = 25.3$ Hz), 49.3. ^{19}F NMR (376 MHz, CDCl_3) δ -62.70 (major diastereomer), -62.75 (minor diastereomer), -63.36 (d, $J = 8.9$ Hz, minor diastereomer), -64.55 (d, $J = 9.1$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{24}\text{H}_{18}\text{F}_6$ 419.1229, found 419.1228.



(E)-4-(2,4-Dichlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl dibenzene (3ja).


Compound **3ja** was obtained as a pale yellow oil in 71% yield (33.6 mg, 0.080 mmol) using Method A. The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 0.8 mL/min, $\lambda = 254$ nm): major diastereomer, 93% *ee*, t_R (major) = 6.0 min., t_R (minor) = 6.4 min.; minor diastereomer, 93% *ee*, t_R (major) = 7.0 min., t_R (minor) = 13.1 min. ^1H NMR (400 MHz, CDCl_3) δ 7.51 (d, $J = 8.5$ Hz, 1H), 7.42 (d, $J = 2.2$ Hz, 1H), 7.37 – 7.32 (m, 4H), 7.32 – 7.26 (m, 2H), 7.23 – 7.19 (m, 2H), 7.14 – 7.05 (m, 3H), 6.19 (d, $J = 15.7$ Hz, 1H), 6.09 (dd, $J = 15.7, 8.7$ Hz, 1H), 4.63 (dq, $J = 9.5, 9.5$ Hz, 1H), 4.05 (dd, $J = 9.5, 9.5$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.9, 136.7, 136.2, 134.5, 132.4, 130.1, 129.9, 129.6, 128.9, 128.7, 128.6 (q, $J_{\text{C-F}} = 281.6$ Hz), 128.4, 127.8, 127.6, 127.6, 127.3, 126.2, 50.6, 49.9 (q, $J_{\text{C-F}} = 25.2$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -63.85 (d, $J = 8.9$ Hz, major diastereomer), -64.09 (d, $J = 8.9$ Hz, minor diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{Cl}_2\text{F}_3$ 419.0576, found 419.0574.



(E)-4-(4-Bromo-2-chlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl dibenzene (3ka).

Compound **3ka** was obtained as a colorless solid in 79% yield (109.8 mg, 0.24 mmol) using Method A. The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were


determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 0.8 mL/min, $\lambda = 254$ nm): major diastereomer, 93% *ee*, t_R (major) = 6.3 min., t_R (minor) = 6.9 min.; minor diastereomer, >99% *ee*, t_R (major) = 7.4 min., t_R (minor) = 12.7 min. ^1H NMR (400 MHz, CDCl_3) δ 7.57 (dd, $J = 1.2$ Hz, 1H), 7.45 – 7.42 (m, 2H), 7.38 – 7.25 (m, 5H), 7.23 – 7.09 (m, 5H), 6.18 (d, $J = 15.7$ Hz, 1H), 6.08 (dd, $J = 15.7, 8.8$ Hz, 1H), 4.60 (dq, $J = 9.9, 8.7$ Hz, 1H), 4.04 (dd, $J = 9.9, 8.8$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.8, 136.7, 136.4, 132.5, 132.3, 131.5 (q, $J_{\text{C-F}} = 1.9$ Hz), 130.5, 130.4 (q, $J_{\text{C-F}} = 1.8$ Hz), 128.8, 128.6, 128.4, 127.7, 127.5, 127.2, 127.0 (q, $J_{\text{C-F}} = 281.8$ Hz), 126.2, 122.3, 50.5, 49.9 (q, $J_{\text{C-F}} = 25.3$ Hz). ^{19}F NMR (376 MHz, cdcl_3) δ -63.86 (d, $J = 8.8$ Hz, major diastereomer), -64.08 (d, $J = 8.4$ Hz, minor diastereomer). EA Found: C, 59.6; H, 3.9. $\text{C}_{23}\text{H}_{17}\text{BrClF}_3$ requires C, 59.3; H, 3.7%.



(E)-(4-(4-Bromo-2,6-difluorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3la).


Compound **3la** was obtained as a colorless solid in 87% yield (30.4 mg, 0.065 mmol) after 48 hours using Method A. The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK IB, Hexanes/DCM 99:1, flow rate 0.3 mL/min, $\lambda = 254$ nm): major diastereomer, 90.4% *ee*, t_R (major) = 25.3 min., t_R (minor) = 24.5 min.; minor diastereomer, 97% *ee*, t_R (major) = 23.0 min., t_R (minor) = 22.4 min. ^1H NMR (400 MHz, CDCl_3) δ 7.39 – 7.34 (m, 4H), 7.28 (m, 1H), 7.22 – 7.14 (m, 3H), 7.11 – 7.05 (m, 4H), 6.36 (d, $J = 15.6$ Hz, 1H), 6.01 (dd, $J = 15.7, 8.5$ Hz, 1H), 4.37 (dd, $J = 8.4, 8.4$ Hz, 1H), 4.36 (dq, $J = 9.7, 9.7$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.6 (d, $J_{\text{C-F}} = 255.6$ Hz), 161.2 (d, $J_{\text{C-F}} = 253.4$ Hz), 141.1, 136.6, 131.7, 129.1, 128.9, 128.4, 127.6, 127.3, 126.9, 126.3 (q, $J_{\text{C-F}} = 281.9$ Hz), 126.2, 122.5

(dd, $J_{C-F} = 12.9$ Hz), 116.3 (d, $J_{C-F} = 27.7$ Hz), 115.4 (d, $J_{C-F} = 28.7$ Hz), 110.3 (dd, $J_{C-F} = 17.8$ Hz), 47.4, 45.7 (q, $J_{C-F} = 27.0$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -63.31 (dd, $J = 16.4, 8.5$ Hz, minor diastereomer), -63.60 (dd, $J = 17.0, 7.5$ Hz, major diastereomer), -105.90 (dq, $J = 15.9, 15.9$ Hz, major diastereomer), -106.27 (dq, $J = 11.23, 11.23$ Hz, minor diastereomer), -111.77 (d, $J = 7.4$ Hz, minor diastereomer), -111.93 (d, $J = 8.7$ Hz, major diastereomer). EA Found: C, 59.4; H, 3.6. $\text{C}_{23}\text{H}_{16}\text{BrF}_5$ requires C, 59.1; H, 3.45%.




(E)-(4-(4-Bromo-3-nitrophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ma).

Compound **3ma** was obtained as a colorless oil in 72% yield (25.8 mg, 0.054 mmol) after 48 hours using Method B. The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 87% *ee*, t_R (major) = 14.8 min., t_R (minor) = 18.6 min.; minor diastereomer, 94% *ee*, t_R (major) = 39.9 min., t_R (minor) = 24.4 min. ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, $J = 2.2$ Hz, 1H), 7.70 (d, $J = 8.3$ Hz, 1H), 7.36 – 7.25 (m, 5H), 7.24 – 7.14 (m, 6H), 6.35 (d, $J = 15.7$ Hz, 1H), 6.04 (dd, $J = 15.7, 9.3$ Hz, 1H), 4.16 (dd, $J = 8.6, 8.6$ Hz, 1H), 3.82 (dq, $J = 8.7, 8.7$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 140.5, 136.3, 135.2, 134.6, 134.3, 133.6, 129.0, 128.6, 127.9, 127.6 (q, $J_{C-F} = 281.2$ Hz), 127.6, 127.5, 127.3, 126.9, 126.3, 114.6, 55.2 (q, $J_{C-F} = 24.7$ Hz), 49.10. ^{19}F NMR (376 MHz, CDCl_3) δ -63.58 (d, $J = 8.7$ Hz, minor diastereomer), -64.74 (d, $J = 8.8$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{HCOO}]^-$ calcd for $\text{C}_{23}\text{H}_{17}\text{BrF}_3\text{NO}_2$ 520.0377, found 520.0368.




(E)-1-(4-(3,5-Bis(4-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cb).

Compound **3cb** was obtained as a pale yellow oil in 79% yield (41 mg, 0.074 mmol) using Method A. The *dr* was determined to be 1:5 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 98:2, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, 91% *ee*, t_R (major) = 40.4 min., t_R (minor) = 60.4 min.; minor diastereomer, > 99 *ee*, t_R (major) = 71.7 min., t_R (minor) = 81.1 min. ^1H NMR (400 MHz, CDCl_3) δ 7.92 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 8.4$ Hz, 2H), 7.38 – 7.29 (m, 4H), 7.08 (dd, $J = 8.5, 5.8$ Hz, 2H), 6.96 (d, $J = 8.5$ Hz, 2H), 6.17 (d, $J = 15.7$ Hz, 1H), 6.00 (dd, $J = 15.7, 8.7$ Hz, 1H), 4.12 (dd, $J = 8.6, 8.6$ Hz, 1H), 3.77 (dq, $J = 8.8, 8.8$ Hz, 1H), 2.58 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 200.1, 142.5, 141.0, 139.7, 138.0, 134.6, 134.3, 132.6, 132.2, 132.2, 131.7 (q, $J_{\text{C-F}} = 282.0$ Hz), 131.3, 131.3, 130.4, 124.3, 123.9, 58.5 (q, $J_{\text{C-F}} = 25.0$ Hz), 51.5, 29.3. ^{19}F NMR (376 MHz, CDCl_3) δ -63.43 (d, $J = 8.9$ Hz, minor diastereomer), -64.31 (d, $J = 8.9$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{Br}_2\text{F}_3\text{O}$ 552.9809, found 552.9783.



(E)-1-(4-(3,5-Bis(3-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cc).

Compound **3cc** was obtained as a pale yellow oil in 88% yield (37 mg, 0.067 mmol) after 48 hours using Method A. The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, > 99% *ee*, t_R (major) = 16.3 min., t_R (minor) = 19.8 min.; minor diastereomer, > 99% *ee*, t_R (major) = 22.1 min., t_R (minor) = 38.0 min. ^1H NMR (400 MHz, CDCl_3) δ 7.94 (d, $J = 8.4$ Hz, 2H), 7.40 – 7.32 (m, 4H), 7.25 – 7.23 (m, 2H), 7.19 (m, 1H), 7.13 (m, 1H), 7.07 (m, 1H), 7.01 (m, 1H), 6.18 (d, $J = 15.6$ Hz, 1H), 5.99 (dd, $J = 15.7, 9.0$ Hz, 1H), 4.11 (dd, $J = 8.8, 8.8$ Hz, 1H), 3.79 (dq, $J = 8.8, 8.8$ Hz, 1H), 2.59 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 200.1, 145.8, 141.2, 140.9, 139.8, 134.5, 133.5, 133.3, 133.2, 133.1, 132.7, 132.6, 132.0, 131.7, 131.3, 129.1, 129.0 (q, $J_{\text{C-F}} = 281.0$ Hz), 127.6, 125.5, 125.4, 58.4 (q, $J_{\text{C-F}} = 25.4$ Hz), 51.8, 29.3. ^{19}F NMR (376 MHz, CDCl_3) δ -63.43 (d, $J = 8.9$ Hz, minor diastereomer), -64.35 (d, $J = 8.8$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{Br}_2\text{F}_3\text{O}$ 552.9809, found 552.9808.




(E)-1-(4-(1,1,1-Trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd).


Compound **3cd** was obtained as a white paste in 76% yield (34 mg, 0.068 mmol) using Method A.

The *dr* was determined to be 1:3 by crude ^{19}F NMR spectroscopy. The *ee*'s were determined by HPLC (CHIRALPAK AD-H, Hexanes/IPA 99:1, flow rate 1.0 mL/min, $\lambda = 254$ nm): major diastereomer, > 99% *ee*, t_R (major) = 16.9 min., t_R (minor) = 21.6 min.; minor diastereomer, > 99% *ee*, t_R (major) = 20.2 min., t_R (minor) = 33.2 min. ^1H NMR (400 MHz, CDCl_3) δ 8.36 (d, $J = 8.7$ Hz, 1H), 7.97 – 7.88 (m, 3H), 7.83 – 7.74 (m, 2H), 7.74 – 7.63 (m, 3H), 7.57 (m, 1H), 7.47 – 7.26 (m, 7H), 7.22 – 7.13 (m, 2H), 6.30 (dd, $J = 15.4, 9.2$ Hz, 1H), 5.26 (dd, $J = 7.7, 7.7$ Hz, 1H), 4.10 (dq, $J = 9.6, 6.9$ Hz, 1H), 2.57 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 200.2, 141.1, 139.6, 139.5, 137.6, 137.0, 136.1, 133.8, 133.7, 133.5, 133.3, 133.0, 132.2, 131.0, 130.7, 130.6, 130.3 (q, $J_{\text{C-F}} = 282.1$ Hz), 129.4, 128.6, 128.6, 128.5, 128.2, 127.9, 126.7, 126.5, 125.1, 57.9 (q, $J_{\text{C-F}} = 25.2$ Hz), 46.7, 29.3. ^{19}F NMR (376 MHz, CDCl_3) δ -62.94 (d, $J = 8.8$ Hz, minor diastereomer), -64.45 (d, $J = 9.4$ Hz, major diastereomer). HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{25}\text{F}_3\text{O}$ 495.1930, found 495.1923.


5. Product derivatizations




A solution of AD-mix- α (180.0 mg), methanesulfonamide (13.3 mg, 0.14 mmol), and **3ca** (56 mg, 0.14 mmol, *dr* = 1:10) was stirred in 4 mL of a 1:1 water/*t*-BuOH mixture at 0 °C. After 48 hours, excess Na₂SO₃ was added and the reaction was stirred for another hour. To the mixture was added CH₂Cl₂ and the organic layer was washed with water and dried over Na₂SO₄. The crude product was purified by flash chromatography on silica gel using EtOAc:hexanes (1:5) as the mobile phase to obtain **5** as a colorless oil in 78% yield (47.0 mg, 0.11 mmol). The *dr* was determined to be 1:12 by ¹⁹F NMR spectroscopy. The *ee* was determined to be 94% by ¹⁹F NMR spectroscopy integration of the resulting diastereomers. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, *J* = 8.0 Hz, 2H), 7.41 – 7.26 (m, 10H), 6.94 – 6.88 (m, 2H), 4.14 (dq, *J* = 11.8, 8.9 Hz, 1H), 3.92 (d, *J* = 9.0 Hz, 1H), 3.53 (dd, *J* = 9.0, 2.4 Hz, 1H), 2.85 (dd, *J* = 11.8, 2.4 Hz, 1H), 2.62 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 200.4, 142.9, 142.1, 139.6, 139.5, 133.1, 132.2, 131.6, 131.4, 131.4, 131.2 (q, *J*_{C-F} = 281.4 Hz), 130.7, 130.2, 78.5, 77.1, 55.7 (q, *J*_{C-F} = 24.8 Hz), 49.2, 29.3. ¹⁹F NMR (376 MHz, CDCl₃) δ -61.13 (d, *J* = 9.8 Hz, minor diastereomer), δ -63.07 (d, *J* = 8.7 Hz, major diastereomer), -63.49 (d, *J* = 9.2 Hz, minor diastereomer). HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd for C₂₅H₂₃F₃O₃ 429.1672, found 429.1665.



A solution of **3ca** (39.0 mg, 0.1 mmol, *dr* = 1:10) in 1.5 mL CHCl₃ was cooled to 0 °C followed by dropwise addition of a solution of 3-chloroperbenzoic acid ($\leq 77\%$, 34.0 mg, 0.15 mmol) in 1.5 mL CHCl₃. The reaction mixture was left to warm to room temperature overnight and quenched with 5% aq. Na₂CO₃. The solution was extracted with EtOAc (3 x 5 mL) and the organic layers were combined and washed with Na₂CO₃ solution and brine. The organic solution was dried over Na₂SO₄ and purified by silica gel chromatography using EtOAc:hexanes (1:25) as the mobile phase to obtain **6** as a white solid in 77% yield (31.0 mg, 0.076 mmol). The *dr* was determined to be 1:4 by ¹⁹F NMR spectroscopy. ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, *J* = 8.3 Hz, 2H), 7.45 – 7.41 (m, 2H), 7.40 – 7.36 (m, 2H), 7.34 – 7.30 (m, 3H), 7.18 – 7.12 (m, 3H), 6.77 – 6.69 (m, 2H), 3.89 (dq, *J* = 9.6, 9.0 Hz, 1H), 3.28 (dd, *J* = 10.1, 7.6 Hz, 1H), 3.22 (d, *J* = 2.0 Hz, 1H), 2.87 (dd, *J* = 7.7, 1.9 Hz, 1H), 2.58 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 199.9, 141.4, 140.3, 139.9, 138.7, 132.8, 132.1, 131.6, 131.4, 131.1 (q, *J*_{C-F} = 290.7 Hz), 130.9, 130.8, 130.5, 127.8, 66.8, 62.8, 56.7 (q, *J*_{C-F} = 26.0 Hz), 51.4, 29.3. ¹⁹F NMR (376 MHz, CDCl₃) δ -63.74 (d, *J* = 8.5 Hz, major diastereomer), -64.50 (d, *J* = 9.3 Hz, minor diastereomer). HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd for C₂₅H₂₁F₃O₂ 411.1566, found 411.1571.




Compound **3ba** (85.0 mg, 0.2 mmol, *dr* = 1:10) and *N*-methylmorpholine *N*-oxide (54.0 mg, 0.4 mmol) were stirred in 6.0 mL of ACN/H₂O (4:1) followed by addition of OsO₄ (188.0 μL, 2.5 wt% in *t*-BuOH). The reaction was stirred at room temperature for 24 hours followed by dilution with EtOAc. The organic layer was washed with brine and dried over Na₂SO₄ then purified by silica gel chromatography using EtOAc:hexanes (1:5) as the mobile phase to obtain the dihydroxylated product as a colorless oil in 58% yield (53.0 mg, 0.12 mmol). The diol was dissolved in 1 mL ACN and a solution of NaIO₄ (50.0 mg, 0.24 mmol) in 1 mL H₂O was added to the reaction and left to stir overnight. The reaction mixture was diluted with H₂O and extracted with EtOAc (3 x 5 mL). The organic solution was dried over Na₂SO₄ and purified by silica gel chromatography using EtOAc:hexanes (1:50) as the mobile phase to obtain **7** as a white solid in 58% yield (24.1 mg, 0.069 mmol). The *dr* was determined to be 1:10 by ¹⁹F NMR spectroscopy. ¹H NMR (400 MHz, CDCl₃) δ 9.40 (d, *J* = 1.8 Hz, 1H), 8.09 – 8.01 (m, 2H), 7.49 (d, *J* = 8.2 Hz, 2H), 7.45 – 7.34 (m, 3H), 7.33 – 7.27 (m, 2H), 4.43 (dd, *J* = 11.0, 1.8 Hz, 1H), 4.37 (q, *J* = 7.1 Hz, 2H), 4.21 (dq, *J* = 11.2, 8.8 Hz, 1H), 1.38 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 197.3, 168.6, 141.2, 134.3, 133.5, 132.7, 132.4, 132.0, 131.4, 128.5 (q, *J*_{C-F} = 282.2 Hz), 63.8, 62.2, 53.3 (q, *J*_{C-F} = 26.2 Hz), 17.0. ¹⁹F NMR (376 MHz, CDCl₃) δ -64.21 (d, *J* = 8.7 Hz, major diastereomer), -66.57 (d, *J* = 9.0 Hz, minor diastereomer). HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd for C₁₉H₁₇F₃O₃ 351.1203, found 351.1204.




Compound **3ka** (44.0 mg, 0.1 mmol, *dr* = 1:2), boronic acid (23.0 mg, 0.15 mmol), K₂CO₃ (21.0 mg, 0.12 mmol), and Pd(PPh₃)₄ (6.0 mg, 5 mol%) were combined in 2.0 mL THF/H₂O (4:1) under nitrogen atmosphere. The solution was heated to reflux for 48 hours then cooled to room temperature, extracted with EtOAc (3 x 5 mL) and washed with brine. The organic solution was dried over Na₂SO₄ and purified by silica gel chromatography using EtOAc:hexanes as the mobile phase to obtain **8** as a white solid in 89% yield (41.5 mg, 0.084 mmol). The *dr* was determined to be 1:2 by ¹⁹F NMR spectroscopy. ¹H NMR (400 MHz, CDCl₃) δ 7.58 (d, *J* = 1.6 Hz, 2H), 7.48 (dd, *J* = 8.6, 1.5 Hz, 3H), 7.39 – 7.32 (m, 5H), 7.23 – 7.08 (m, 5H), 6.98 – 6.93 (m, 2H), 6.19 (d, *J* = 15.8 Hz, 1H), 6.16 (dd, *J* = 15.4, 7.8 Hz, 1H), 4.69 (dq, *J* = 9.2, 9.2 Hz, 1H), 4.10 (dd, *J* = 8.8, 8.8 Hz, 1H), 3.83 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 159.7, 141.9, 141.3, 137.0, 135.9, 132.2, 131.4, 130.2, 129.3, 128.8, 128.4, 128.1, 127.9, 127.9 (q, *J*_{C-F} = 282.1 Hz), 127.8, 127.5, 127.3, 127.1, 126.2, 125.3, 114.3, 55.3, 50.6, 49.9 (q, *J*_{C-F} = 25.8 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -63.78 (d, *J* = 8.8 Hz, major diastereomer), -63.95 (d, *J* = 8.8 Hz, minor diastereomer). HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd for C₃₀H₂₄ClF₃O 493.1541, found 493.1534.

6. ^1H , ^{13}C , and ^{19}F NMR Spectra


^1H NMR spectrum of 4-(2,2-difluorovinyl)-2-methyl-1-nitrobenzene (**1g**)




^{13}C NMR spectrum of 4-(2,2-difluorovinyl)-2-methyl-1-nitrobenzene (**1g**)




^{19}F NMR spectrum of 4-(2,2-difluorovinyl)-2-methyl-1-nitrobenzene (**1g**)




¹H NMR spectrum of 4-Bromo-2-chloro-1-(2,2-difluorovinyl)benzene (1k)




¹³C NMR spectrum of 4-Bromo-2-chloro-1-(2,2-difluorovinyl)benzene (1k)




¹⁹F NMR spectrum of 4-Bromo-2-chloro-1-(2,2-difluorovinyl)benzene (1k)




¹H NMR spectrum of 5-Bromo-2-(2,2-difluorovinyl)-1,3-difluorobenzene (11).




¹³C NMR spectrum of 5-Bromo-2-(2,2-difluorovinyl)-1,3-difluorobenzene (11).




¹⁹F NMR spectrum of 5-Bromo-2-(2,2-difluorovinyl)-1,3-difluorobenzene (11).




¹H NMR spectrum of 1-Bromo-4-(2,2-difluorovinyl)-2-nitrobenzene (1m).




¹³C NMR spectrum of 1-Bromo-4-(2,2-difluorovinyl)-2-nitrobenzene (1m).




¹⁹F NMR spectrum of 1-Bromo-4-(2,2-difluorovinyl)-2-nitrobenzene (1m).




¹H NMR spectrum of methyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3aa)




¹³C NMR spectrum of methyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3aa)




¹⁹F NMR spectrum of methyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3aa)




¹H NMR spectrum of ethyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3ba)




¹³C NMR spectrum of ethyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3ba)




¹⁹F NMR spectrum of ethyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3ba)




¹H NMR spectrum of (*E*)-1-(4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)phenyl)ethan-1-one (3ca)




¹³C NMR spectrum of (*E*)-1-(4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)phenyl)ethan-1-one (3ca)




¹⁹F NMR spectrum of (*E*)-1-(4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)phenyl)ethan-1-one (3ca)




¹H NMR spectrum of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzaldehyde (3da)




¹³C NMR spectrum of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzaldehyde (3da)




¹⁹F NMR spectrum of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzaldehyde (3da)




¹H NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ea)




¹³C NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ea)




¹⁹F NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ea)




¹H NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(4-(methylsulfonyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3fa)




¹³C NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(4-(methylsulfonyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3fa)




¹⁹F NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(4-(methylsulfonyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3fa)




¹H NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(3-methyl-4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ga)




¹³C NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(3-methyl-4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ga)




¹⁹F NMR spectrum of (*E*)-(5,5,5-trifluoro-4-(3-methyl-4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ga)




¹H NMR spectrum of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzotrile (3ha)




¹³C NMR spectrum of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzotrile (3ha)




¹⁹F NMR spectrum of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzotrile (3ha)




¹H NMR spectrum of (*E*)-(5,5,5-Trifluoro-4-(4-(trifluoromethyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3ia)




¹³C NMR spectrum of (*E*)-(5,5,5-Trifluoro-4-(4-(trifluoromethyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3ia)




¹⁹F NMR spectrum of (*E*)-(5,5,5-Trifluoro-4-(4-(trifluoromethyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3ia)




¹H NMR spectrum of (*E*)-(4-(2,4-Dichlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ja)




¹³C NMR spectrum of (*E*)-(4-(2,4-Dichlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ja)




¹⁹F NMR spectrum of (*E*)-(4-(2,4-Dichlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ja)




¹H NMR spectrum of (*E*)-(4-(4-Bromo-2-chlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ka)




¹³C NMR spectrum of (*E*)-(4-(4-Bromo-2-chlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ka)




¹⁹F NMR spectrum of (*E*)-(4-(4-Bromo-2-chlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ka)




¹H NMR spectrum of (*E*)-(4-(4-Bromo-2,6-difluorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3la)




¹³C NMR spectrum of (*E*)-(4-(4-Bromo-2,6-difluorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3la)




¹⁹F NMR spectrum of (*E*)-(4-(4-Bromo-2,6-difluorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3la)




¹H NMR spectrum of (*E*)-(4-(4-Bromo-3-nitrophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ma)




¹³C NMR spectrum of (*E*)-(4-(4-Bromo-3-nitrophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ma)




¹⁹F NMR spectrum of (*E*)-(4-(4-Bromo-3-nitrophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ma)




¹H NMR spectrum of (*E*)-1-(4-(3,5-bis(4-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cb)




¹³C NMR spectrum of (*E*)-1-(4-(3,5-bis(4-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cb)




¹⁹F NMR spectrum of (*E*)-1-(4-(3,5-bis(4-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cb)




¹H NMR spectrum of (*E*)-1-(4-(3,5-bis(3-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cc)




¹³C NMR spectrum of (*E*)-1-(4-(3,5-bis(3-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cc)




¹⁹F NMR spectrum of (*E*)-1-(4-(3,5-bis(3-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cc)




¹H NMR spectrum of (*E*)-1-(4-(1,1,1-trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd)




¹³C NMR spectrum of (*E*)-1-(4-(1,1,1-trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd)




¹⁹F NMR spectrum of (*E*)-1-(4-(1,1,1-trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd)




¹H NMR spectrum of 1-(4-(1,1,1-trifluoro-4,5-dihydroxy-3,5-diphenylpentan-2-yl)phenyl)ethan-1-one (5).




¹³C NMR spectrum of 1-(4-(1,1,1-trifluoro-4,5-dihydroxy-3,5-diphenylpentan-2-yl)phenyl)ethan-1-one (5).




¹⁹F NMR spectrum of 1-(4-(1,1,1-trifluoro-4,5-dihydroxy-3,5-diphenylpentan-2-yl)phenyl)ethan-1-one (5).




¹H NMR spectrum of 1-(4-(1,1,1-trifluoro-3-phenyl-3-(3-phenyloxiran-2-yl)propan-2-yl)phenyl)ethan-1-one (6)




¹³C NMR spectrum of 1-(4-(1,1,1-trifluoro-3-phenyl-3-(3-phenyloxiran-2-yl)propan-2-yl)phenyl)ethan-1-one (6)




¹⁹F NMR spectrum of 1-(4-(1,1,1-trifluoro-3-phenyl-3-(3-phenyloxiran-2-yl)propan-2-yl)phenyl)ethan-1-one (6)




¹H NMR spectrum of ethyl 4-(1,1,1-trifluoro-4-oxo-3-phenylbutan-2-yl)benzoate (7)




¹³C NMR spectrum of ethyl 4-(1,1,1-trifluoro-4-oxo-3-phenylbutan-2-yl)benzoate (7)




¹⁹F NMR spectrum of ethyl 4-(1,1,1-trifluoro-4-oxo-3-phenylbutan-2-yl)benzoate (7)




¹H NMR spectrum of (*E*)-3-chloro-4'-methoxy-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)-1,1'-biphenyl (8)



¹³C NMR spectrum of (*E*)-3-chloro-4'-methoxy-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)-1,1'-biphenyl (8)




¹⁹F NMR spectrum of (*E*)-3-chloro-4'-methoxy-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)-1,1'-biphenyl (8)




7. HPLC chromatograms


HPLC of *racemic* methyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3aa)




HPLC of methyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3aa)




HPLC of racemic ethyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3ba)




HPLC of ethyl (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzoate (3ba)




HPLC of racemic (*E*)-1-(4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)phenyl)ethan-1-one (3ca)




HPLC of (*E*)-1-(4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)phenyl)ethan-1-one (3ca)




HPLC of racemic (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzaldehyde (3da)




HPLC of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzaldehyde (3da)




HPLC of racemic (E)-(5,5,5-trifluoro-4-(4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ea)




HPLC of (E)-(5,5,5-trifluoro-4-(4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ea)




HPLC of racemic (*E*)-(5,5,5-trifluoro-4-(4-(methylsulfonyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3fa)




HPLC of (*E*)-(5,5,5-trifluoro-4-(4-(methylsulfonyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (3fa)




HPLC of racemic (*E*)-(5,5,5-trifluoro-4-(3-methyl-4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ga)




HPLC of (*E*)-(5,5,5-trifluoro-4-(3-methyl-4-nitrophenyl)pent-1-ene-1,3-diyl)dibenzene (3ga)




HPLC of racemic (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzotrile (3ha)




HPLC of (*E*)-4-(1,1,1-trifluoro-3,5-diphenylpent-4-en-2-yl)benzotrile (3ha)




HPLC of racemic (*E*)-(5,5,5-Trifluoro-4-(4-(trifluoromethyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (**3ia**)




HPLC of (*E*)-(5,5,5-Trifluoro-4-(4-(trifluoromethyl)phenyl)pent-1-ene-1,3-diyl)dibenzene (**3ia**)




HPLC of *racemic* (*E*)-(4-(2,4-Dichlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ja)




HPLC of (*E*)-(4-(2,4-Dichlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ja)




HPLC of racemic (*E*)-(4-(4-Bromo-2-chlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ka)




HPLC of (*E*)-(4-(4-Bromo-2-chlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ka)




HPLC of *racemic* (*E*)-(4-(4-Bromo-2,6-difluorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (31a)




HPLC of (*E*)-(4-(4-Bromo-2,6-difluorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (31a)




HPLC of racemic (*E*)-(4-(4-Bromo-3-nitrophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ma).




HPLC of (*E*)-(4-(4-Bromo-3-nitrophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ma).




HPLC of racemic (*E*)-1-(4-(3,5-bis(4-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cb)




HPLC of (*E*)-1-(4-(3,5-bis(4-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cb)




HPLC of racemic (*E*)-1-(4-(3,5-bis(3-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cc)




HPLC of (*E*)-1-(4-(3,5-bis(3-bromophenyl)-1,1,1-trifluoropent-4-en-2-yl)phenyl)ethan-1-one (3cc)




HPLC of the major diastereomer of *racemic* (*E*)-1-(4-(1,1,1-trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd)




HPLC of the major diastereomer of (*E*)-1-(4-(1,1,1-trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd)



HPLC of the minor diastereomer of *racemic* (*E*)-1-(4-(1,1,1-trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd)




HPLC of the minor diastereomer of (*E*)-1-(4-(1,1,1-trifluoro-3,5-di(naphthalen-1-yl)pent-4-en-2-yl)phenyl)ethan-1-one (3cd)




8. Crystallographic data


(3*S*,4*R*,*E*)-(4-(2,4-Dichlorophenyl)-5,5,5-trifluoropent-1-ene-1,3-diyl)dibenzene (3ja, major diastereomer)



A single crystal was obtained by slow evaporation of a solution containing **3ja** in dichloromethane. Single crystal X-ray analysis was performed at 100 K using a Bruker APEX DUO equipped with a Cu-K α ($\lambda = 1.54178 \text{ \AA}$) micro-focus source, an ApexII detector, and an Oxford 700 Cryostream. Data were integrated using the Bruker SAINT program. Structure solution and refinement was performed using the SHELXTL/PC suite and ShelXle. Intensities were corrected for Lorentz and polarization effects and an empirical absorption correction was applied using Blessing's method as incorporated into the program SADABS. Non-hydrogen atoms were refined with anisotropic displacement parameters. Crystal data: C₂₃H₁₇C₁₂F₃, $M = 421.26$, colorless rod, 0.044 x 0.121 x 0.418 mm³, orthorhombic, space group P21212, $a = 16.9540(3)$, $b = 20.1285(3)$, $c = 5.70930(10)$ \AA , $V = 1948.35(6) \text{ \AA}^3$, $Z = 4$. Absolute structure parameter = 0.011(4) (Flack, H. D. Acta Cryst. 1983, A39, 876-881). CCDC 2383108

1-(4-((2*R*,3*S*)-1,1-Trifluoro-3-phenyl-3-((2*S*,3*S*)-3-phenyloxiran-2-yl)propan-2-yl)phenyl)ethan-1-one (6, major diastereomer)





A single crystal was obtained by slow evaporation of a solution containing **6** in dichloromethane. Single crystal X-ray analysis was performed at 100 K using a Bruker APEX DUO equipped with a Cu-K α ($\lambda = 1.54178 \text{ \AA}$) micro-focus source, an ApexII detector, and an Oxford 700 Cryostream. Data were integrated using the Bruker SAINT program. Structure solution and refinement was performed using the SHELXTL/PC suite and ShelXle. Intensities were corrected for Lorentz and polarization effects and an empirical absorption correction was applied using Blessing's method as incorporated into the program SADABS. Non-hydrogen atoms were refined with anisotropic displacement parameters. Crystal data: C₂₅H₂₁F₃O₂, $M = 410.42$, colorless plate, 0.074 x 0.31 x 0.482 mm³, orthorhombic, space group P2₁2₁2₁, $a = 8.9675(2)$, $b = 9.7971(2)$, $c = 22.7498(5) \text{ \AA}$, $V = 1998.70(7) \text{ \AA}^3$, $Z = 4$. Absolute structure parameter = 0.01(3) (Flack, H. D. Acta Cryst. 1983, A39, 876-881). CCDC 2383107

9. References

- 1 P. Tian, C.-Q. Wang, S.-H. Cai, S. Song, L. Ye, C. Feng, T.-P. Loh. *J. Am. Chem. Soc.* **2016**, *138*, 15869–15872.
- 2 T.-Y. Lin, Z. Pan, Y. Tu, S. Zhu, H.-H. Wu, Y. Liu, Z. Li, J. Zhang. *Angew. Chem. Int. Ed.* **2020**, *59*, 22957–22962.
- 3 Yuan, F-Q.; Gao, L-Z.; Han, F-S. *Chem. Commun.* **2011**, *47*, 5289–5291.
- 4 S. Jayakumar, N. Kumarswamyreddy, M. Prakash, V. Kesavan, *Org. Lett.* **2015**, *17*, 1066–1069.